New York—Management of metastatic, clear-cell renal cell carcinoma has been significantly advanced by the development of the oral small-molecule kinase inhibitors sunitinib malate (Sutent) and sorafenib (Nexavar), recent results from two large, international, randomized, double-blind, phase III trials indicate. Both studies appeared in the Jan. 11, 2007 issue of the New England Journal of Medicine (2007; 356:115-24 and 125-34).
Cheryl Guttman Krader
Baltimore—PSA velocity measured 10 to 15 years prior to prostate cancer diagnosis is a significant predictor of cancer-specific survival 2 to 3 decades later, according to the results of a study published in the Journal of the National Cancer Institute (2006; 98:1521-7).
Rochester, MN—Men who take non-steroidal anti-inflammatory drugs (NSAIDs) daily have a decreased risk for developing BPH and associated lower urinary tract symptoms, according to analyses of data collected in a longitudinal population-based cohort study of aging men.
Chicago—In patients with a contrast-enhancing renal mass, delayed intervention after watchful waiting does not adversely affect pathologic outcomes, results of a retrospective study designed to gain insight into the natural history of "incidentalomas" indicate. This holds true even for some lesions that are relatively large at diagnosis or found on follow-up to be rapidly growing, researchers from University of North Carolina at Chapel Hill reported at the American College of Surgeons clinical congress.
Chicago—Initial analyses from a retrospective study involving almost 600 men undergoing prostate needle biopsy show no association between inflammation on initial or subsequent biopsy and prostate cancer. However, the investigators from Harvard Medical School are withholding any conclusions while they continue their research.
Chicago—Sextant biopsy with a transition zone or a laterally directed template loses efficacy in prostate cancer diagnosis with repeat testing, but only after four negative biopsies have been taken, researchers from Harvard Medical School reported at the American College of Surgeons clinical congress here.
Boston—A study investigating a treatment sample of men diagnosed with sexual compulsivity suggests that prescription and non-prescription use of phosphodiesterase type-5 inhibitors is common in that population. This finding should alert physicians who prescribe medications for erectile dysfunction to maintain an index of patients with a suspected sexual compulsivity problem and to be attentive to clues of potential drug misuse, according to the researchers.
Boston—Gonadotropin-releasing hormone (GnRH) agonist therapy for locoregional prostate cancer is associated with significantly increased risks of diabetes as well as cardiovascular disease morbidity and mortality, according to the results of a population-based, observational cohort study.
Miami—Expression of cyclooxygenase-2 (COX-2) in radical prostatectomy specimens is an independent predictor of prostate cancer recurrence, according to a study reported by researchers from the University of Miami's Miller School of Medicine.
Ann Arbor, MI—Results of a study from the University of Michigan here provide further evidence that the incidence of kidney cancer and the rate of surgical treatment are both on the rise. However, those trends are primarily accounted for by the identification and management of small, presumably curable renal masses (?4 cm). Meanwhile, mortality rates in kidney cancer patients have also been increasing, driven by worsening outcomes of patients with the largest tumors (>7 cm).